Ovarian cancer is a steady, silent killer--its diagnosis is easy to miss and there are few options to prevent recurrence after treatment. Australian biotech company Prima BioMed's vaccine, known as Cvac, is in clinical development, and Sarasota Memorial Hospital in the U.S. will be the first site in the world approved to begin enrolling patients in the company's international Phase II trial. The ovarian cancer vaccine is a personalized treatment made from the patient's dendritic cells (white blood cells) and the protein mucin-1. Cvac is designed to prevent recurrence after surgery and chemotherapy in newly diagnosed women. Press release